Long-Acting Fluocinolone Acetonide Intravitreal Implant for Recurrent Bilateral Non-Infectious Posterior Uveitis

Abstract

Purpose Our case emphasizes the utility of long-acting intravitreal fluocinolone implants (YUTIQ) for managing recalcitrant forms of non-infectious posterior uveitis, NIPU. Patient We present a case of bilateral NIPU refractory to topical corticosteroids and intravitreal triamcinolone and dexamethasone. Results Management with bilateral YUTIQ improved local ocular inflammatory control with improved vision and anatomical outcomes. Conclusion NIPU can develop into recurrent forms resistant to short-acting therapeutics. Long-acting efficacy with YUTIQ emphasizes the need to recognize such refractory NIPU cases.

Progress in the Use of Glucocorticoids and Biological Agents in Non-Infectious Uveitis

“…0.18mg Fai (YUTIQ; EyePoint Pharmaceuticals, Watertown, MA, USA) was FDA-approved for the treatment of NIPU in 2018 [27], It has a duration of action of 3 years. Babel et al [28] reported a case of recurrent bilateral NIPU, this patient has a history of localized corticosteroid use and intravitreal injections of TA and DEX, After bilateral injections of 0.18 mg FAi, the patient's BCVA improved from 20/60 to 20/50 in the right eye and from 20/70 to 20/40 in the left eye, and ME and macular leakage were better than before. Similarly, Reddy et al…”

Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations

“…Current evidence suggests that the 0.2 µg/day FAc implant is effective in reducing the need for subsequent treatment with systemic medication [14,15,19,24,25,58,68,71,72].…”